Back to News
Market Impact: 0.25
Nxera Signs AbbVie Deal For IBD Drug Candidate With $100 Mln Upfront, Plus Milestones
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Nxera Pharma said its U.K. subsidiary signed an exclusive global licensing agreement with AbbVie for its EP4 agonist program, including NXE0033744. The announcement did not disclose financial terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ABBV0.45
More News
- Reed Jobs’s Yosemite raises $350 million second fund to make cancer non-lethal
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Snap shares fall over 10% on third-quarter earnings miss
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales
- Drone Attacks Spawn New Insurance Market in Baltics, Poland